Dr. Jie Deng is from Clearwater, Florida and received her Bachelor's degree in Chemistry from the University of Florida. Her interest in studying cancer immunotherapy first stemmed from internships at the National Institutes of Health which led her to pursue MD/PhD training at Dartmouth Medical School. Her PhD research was focused on the transcriptional regulation of immune checkpoints, in particular of VISTA, by the tumor microenvironment and using these insights to inform strategic combinations of immunotherapy for cancer. Upon the completion of her MD/PhD, Dr. Deng spent a year in Chicago for her transitional year internship at Resurrection Medication Center, where she served as Chief Intern. At UCLA, she was selected to participate in the American Board of Radiology Holman Research Pathway, a specialized training mechanism designed for physician scientists. Under this Pathway, she has continued her post-doctoral training in tumor immunotherapy under the mentorship of Dr. Anusha Kalbasi investigating a novel therapeutic approach with intratumoral immunotherapy to reprogram radiation-associated myeloid cells in sarcoma, which is supported by a Jonsson Comprehensive Cancer Center Fellowship Award. Additionally, Dr. Deng has been pursuing clinical trial design and collaboration with industry.